Biomarker Development

Many biomarkers for Alzheimer’s disease have been identified including:

  • amyloid load in the brain
  • amyloid and tau proteins in the CSF
  • metabolic activity in the brain
  • various relative measures of brain atrophy.
Several plasma-based assays are also gaining accuracy in their ability to identify Alzheimer’s disease.

However, no single biomarker has yet been shown to distinguish Alzheimer’s from non-Alzheimer’s with an acceptable level of accuracy to provide clinical and commercial value.

Combining an abnormal biomarker with a sensitive measure of cognition, like our MCI Screen™, is one possible solution to this diagnostic challenge. We are actively engaged with leading diagnostic manufacturers in collaborative efforts to develop a simple and accurate diagnostic test for clinical practice.